Clinical Trials Logo

Clinical Trial Summary

The COVID-19 epidemic has now raged for more than a year with more than 100 million identified cases and nearly 2.5 million deaths worldwide. Since November 2020, we have been witnessing the emergence of viral variants in different regions of the world. This expected genetic drift of the virus, but somewhat abrupt since November, raises questions concerning the characteristics of transmissibility, pathogenicity, sensitivity to possible treatments, and escape from natural or vaccine immunity. The objective of this study is to find out whether the new variants of SARS-CoV-2 are associated with particular clinical forms. The results of this research will provide elements to determine whether the new variants of SARS-CoV-2 are associated with more severe clinical forms.


Clinical Trial Description

SEVASAR is a paired cohort study with retrospective data collection: - Presentation: patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1 - Not exposed: patients hospitalized for COVID-19 with SARS-CoV-2 corresponding to wild variants type 20A. EU1 or 20A. EU2 The severity of illness will be compared between pairs. Disease severity will be assessed according to the following definition: defined by a composite criterion including, at 28 days after hospital admission: WHO scale >5 /11 levels, (death OR need for invasive ventilation OR need for high flow ventilation (Optiflex or NIV or CPAP) or high concentration mask. This event will be taken into account regardless of its time of occurrence between the first day of the hospitalization studied and D29 after hospital admission. ;


Study Design


Related Conditions & MeSH terms

  • Severe Acute Respiratory Syndrome
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

NCT number NCT04863547
Study type Observational [Patient Registry]
Source ANRS, Emerging Infectious Diseases
Contact Xavier Lescure, Pr
Phone 0140258080
Email [email protected]
Status Recruiting
Phase
Start date March 11, 2021
Completion date May 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04768998 - Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
Active, not recruiting NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Recruiting NCT04588363 - COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Completed NCT04725084 - Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Recruiting NCT04851821 - PHYTOTHERAPY IN SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2 Phase 1
Recruiting NCT04391309 - COVID-19 and Anti-CD14 Treatment Trial Phase 2
Completed NCT04343261 - Convalescent Plasma in the Treatment of COVID 19 Phase 2